


WHAT IS CLAIMED IS:

1. A dihydropyrazolopyridine compound of the formula (I):



(I)

wherein


R⁰ is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, formyl, haloalkyl, aminoalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, phenylsulfinyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, phenyl optionally having substituent(s), aromatic heterocyclic group optionally having substituent(s), phenylalkyl optionally having substituent(s), or a group of the formula: -COOR⁸ (wherein R⁸ is hydrogen, alkyl, aryl optionally having substituent(s) or aralkyl optionally having substituent(s));

R¹ and R² are the same or different and each is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, hydroxy, thiol, halogen, amino, formyl, carboxy, cyano, nitro, alkylthio, haloalkyl, aminoalkyl, acylamino, alkoxy, cycloalkoxy, phenoxy, phenylalkoxy, aminoalkoxy, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl,

alkylthioalkyl, phenyl optionally having
substituent(s), aromatic heterocyclic group or
phenylalkyl;

R³ is

- 5 (1) alkyl or haloalkyl,
(2) cycloalkyl,
(3) phenyl optionally having substituent(s),
(4) aromatic heterocyclic group,
(5) a group derived from a benzene ring fused with a
10 saturated or unsaturated 5 or 6 membered carbocyclic
ring,
(6) a group derived from a benzene ring fused with a
saturated or unsaturated 5 to 7 membered carbocyclic
ring containing 1 to 3 heteroatom(s), or
15 (7) a group derived from a 5 to 7 membered saturated
or unsaturated carbocyclic ring containing 1 to 3
heteroatom(s), which is fused with a benzene ring,
wherein the groups of (2) to (7) may have one or more
substituent(s), or
20 a group selected from the groups represented by the
following formulas (II) and (III):



(II)



(III)

25 wherein R⁶ and R⁷ are each phenyl optionally having
substituent(s) or an aromatic heterocyclic group,
or R² and R³ in conjunction form a ring optionally containing
heteroatom(s), wherein the ring may be fused with a
benzene ring optionally having substituent(s);

R^4 is alkoxy carbonyl, alkyl carbonyl, aminocarbonyl, hydrazinocarbonyl, alkylthiocarbonyl, formyl, carbamoyl, alkylthio, phenylthio, alkylsulfinyl, phenylsulfinyl, alkylsulfonyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, phenyl optionally having substituent(s), an aromatic heterocyclic group optionally having substituent(s), cyano or nitro; and

R^5 is hydrogen, cyano, formyl, alkyl, cycloalkyl, alkoxyalkyl, phenoxyalkyl, dialkoxyalkyl, hydroxyalkyl, haloalkyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, alkoxy carbonyl alkyl, alkoxy carbonyl ethenyl, aryl optionally having substituent(s), an aromatic heterocyclic group or phenylalkyl, or a group derived from a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroatom(s), which is fused with a benzene ring; or

phenylaminoalkyl, acyl, acylalkyl, aminocarbonyl, arylaminocarbonyl, a saturated or unsaturated 4 to 7 membered heterocyclic ring optionally having substituent(s), a saturated 3 to 7 membered carbocyclic ring having substituent(s), alkyl substituted by a saturated or unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen atom(s), which optionally has a substituent, or a group of the formula: $-(CR^aR^b)_nNR^{11}R^{12}$ wherein n is an integer of 1 to 4, R^a is hydrogen or alkyl, R^b is

hydrogen or alkyl, R^{11} is hydrogen, alkyl,
alkylsulfonyl, phenylsulfonyl, phenylalkylsulfonyl,
alkylsulfinyl, phenylsulfinyl, phenylalkylsulfinyl,
alkoxycarbonyl, phenoxycarbonyl, phenylalkoxycarbonyl,
5 alkylcarbonyl, phenylcarbonyl or phenylalkylcarbonyl,
and R^{12} is hydrogen or alkyl,
or R^4 and R^5 in conjunction may form a 5 or 6 membered ring
optionally containing heteroatom(s),
provided that when R^0 , R^1 and R^2 are each hydrogen, R^4 is
10 methoxycarbonyl and R^5 is methyl, then R^3 should not be phenyl,
2-chlorophenyl, 3-nitrophenyl, 4-carboxyphenyl or 4-
methoxycarbonylphenyl, and when R^5 is alkyl, then R^4 is not
alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, phenylsulfinyl,
phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, cyano or
15 nitro,
or an optically active form thereof, a pharmaceutically
acceptable salt thereof or a hydrate thereof.

2. The dihydropyrazolopyridine compound of claim 1, wherein
20 R^0 is hydrogen, alkyl, acyl, cycloalkyl, formyl,
haloalkyl, aminoalkyl, alkoxyalkyl, phenoxyalkyl,
hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl,
carboxyalkyl, cycloalkoxyalkyl, alkylsulfinyl,
alkylsulfonyl, phenylsulfonyl, mercaptoalkyl,
25 alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, phenyl
optionally having substituent(s), aromatic
heterocyclic group optionally having substituent(s),
phenylalkyl optionally having substituent(s), or a
group of the formula: $-COOR^8$ (wherein R^8 is hydrogen,
30 alkyl, aryl optionally having substituent(s) or
aralkyl optionally having substituent(s));
 R^1 and R^2 are the same or different and each is hydrogen, alkyl,
acyl, cycloalkyl, hydroxy, thiol, halogen, amino,

formyl, carboxy, cyano, nitro, alkylthio, haloalkyl, aminoalkyl, acylamino, alkoxy, cycloalkoxy, phenoxy, phenylalkoxy, aminoalkoxy, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, alkoxy carbonyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, phenyl optionally having substituent(s), aromatic heterocyclic group or phenylalkyl;

10 R³

is

(1) alkyl or haloalkyl,

(2) cycloalkyl,

(3) phenyl optionally having substituent(s),

(4) aromatic heterocyclic group,

15

(5) a group derived from a benzene ring fused with a saturated or unsaturated 5 or 6 membered carbocyclic ring,


(6) a group derived from a benzene ring fused with a saturated or unsaturated 5 to 7 membered carbocyclic ring containing 1 to 3 heteroatom(s), or

20

(7) a group derived from a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroatom(s), which is fused with a benzene ring, wherein the groups of (2) to (7) may have one or more substituent(s), or

25

a group selected from the groups represented by the following formulas (II) and (III):



(II)



(III)

wherein R⁶ and R⁷ are each phenyl optionally having
substituent(s) or an aromatic heterocyclic group,
or R² and R³ in conjunction form a ring optionally containing
heteroatom(s), wherein the ring may be fused with a
benzene ring optionally having substituent(s);
R⁴ is alkoxy carbonyl, aminocarbonyl, hydrazinocarbonyl,
alkylthiocarbonyl, formyl, carbamoyl, alkylthio,
phenylthio, alkylsulfinyl, phenylsulfinyl,
alkylsulfonyl, phenylsulfonyl, dialkylphosphinyl,
dialkylphosphonyl, cyano or nitro; and
R⁵ is hydrogen, cyano, formyl, alkyl, cycloalkyl,
alkoxyalkyl, phenoxyalkyl, dialkoxyalkyl,
hydroxyalkyl, haloalkyl, carboxyalkyl,
cycloalkoxyalkyl, phenylthio, alkylsulfinyl,
alkylsulfonyl, phenylsulfonyl, mercaptoalkyl,
alkylthioalkyl, alkoxy carbonylalkyl,
alkoxy carbonylethenyl, aryl optionally having
substituent(s), an aromatic heterocyclic group or
phenylalkyl, or a group derived from a 5 to 7
membered saturated or unsaturated carbocyclic ring
containing 1 to 3 heteroatom(s), which is fused with
a benzene ring,
or R⁴ and R⁵ in conjunction may form a 5 or 6 membered ring
optionally containing heteroatom(s),
provided that when R⁰, R¹ and R² are each hydrogen, R⁴ is
methoxycarbonyl and R⁵ is methyl, then R³ should not be phenyl,
2-chlorophenyl, 3-nitrophenyl, 4-carboxyphenyl or 4-
methoxycarbonylphenyl,
or an optically active form thereof, a pharmaceutically
acceptable salt thereof or a hydrate thereof.

3. The dihydropyrazolopyridine compound of claim 2, wherein R⁵

is alkyl having 2 to 8 carbon atoms, cycloalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, phenyl optionally having substituent(s), an aromatic heterocyclic group or phenylalkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

4. The dihydropyrazolopyridine compound of claim 2, wherein R¹ is hydrogen, alkyl, phenyl optionally having substituent(s), an aromatic heterocyclic group or phenylalkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

5. The dihydropyrazolopyridine compound of claim 2, wherein R² is hydrogen or alkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

6. The dihydropyrazolopyridine compound of claim 2, wherein R³ is phenyl optionally having 1 to 3 substituent(s), naphthyl, 2,1,3-benzoxadiazol-4-yl or 3,4-dihydro-2H-benzopyran-8-yl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

7. The dihydropyrazolopyridine compound of claim 2, wherein R⁴ is alkoxycarbonyl having 2 to 5 carbon atoms, cyano or nitro, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

8. The dihydropyrazolopyridine compound of claim 2, wherein R⁵ is alkyl having 2 to 4 carbon atoms, cyclopropyl, phenyl, thienyl or hydroxyalkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

9. The dihydropyrazolopyridine compound of claim 2, wherein R² and R³ in conjunction form a ring containing sulfur atom and the ring is condensed with a benzene ring optionally having substituent(s), or an optically active form thereof, a
5 pharmaceutically acceptable salt thereof or a hydrate thereof.

10. The dihydropyrazolopyridine compound of claim 2, wherein R⁰ is hydrogen or a group of the formula: -COOR⁸ (wherein R⁸ is alkyl, aryl optionally having substituent(s) or aralkyl
10 optionally having substituent(s)), or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

11. The dihydropyrazolopyridine compound of claim 2, which is
15 selected from the group consisting of

- (32) ethyl 4,7-dihydro-4-(2-methoxyphenyl)-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
- (47) ethyl 4-(2-chloro-3-trifluoromethylphenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
- 20 (66) ethyl 4,7-dihydro-4-(naphthalen-1-yl)-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
- (73) ethyl 4-(3,4-dihydro-2H-benzopyran-8-yl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
- (87) ethyl 4-(2-chlorophenyl)-4,7-dihydro-6-(thiophen-2-yl)-
25 2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
- (116) ethyl 4-(2,1,3-benzoxadiazol-4-yl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
- (122) 4-(2,3-dichlorophenyl)-4,7-dihydro-5-nitro-6-propyl-2H-pyrazolo[3,4-b]pyridine,
- 30 (140) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine,
- (147) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-phenyl-2H-pyrazolo[3,4-b]pyridine,

(158) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-phenyl-2H-pyrazolo[3,4-b]pyridine,
 (171) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(thiophen-2-yl)-2H-pyrazolo[3,4-b]pyridine,
 5 (182) ethyl 4-(2-bromo-3-nitrophenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
 (183) ethyl 4-(2-bromo-3-cyanophenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
 (189) 4-(2-bromo-3-nitrophenyl)-5-cyano-4,7-dihydro-6-propyl-
 10 2H-pyrazolo[3,4-b]pyridine,
 (205) ethyl 2-tert-butoxycarbonyl-4-(2-chlorophenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
 (240) ethyl 4-(2,1,3-benzoxadiazol-4-yl)-6-ethyl-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
 15 (257) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-hydroxymethyl-2H-pyrazolo[3,4-b]pyridine,
 (260) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-isopropyl-2H-pyrazolo[3,4-b]pyridine,
 (264) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-
 20 isopropyl-2H-pyrazolo[3,4-b]pyridine, and
 (268) 4-(2-bromo-3-cyanophenyl)-5-cyano-6-cyclopropyl-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine,
 a tautomer, an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

25

12. The dihydropyrazolopyridine compound of claim 1, wherein
 R^0 is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, formyl, haloalkyl, aminoalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl,
 30 carboxyalkyl, cycloalkoxyalkyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, phenylsulfinyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, phenyl optionally having substituent(s),

aromatic heterocyclic group optionally having
substituent(s), phenylalkyl optionally having
substituent(s), or a group of the formula: $-\text{COOR}^8$
(wherein R^8 is hydrogen, alkyl, aryl optionally
5 having substituent(s) or aralkyl optionally having
substituent(s));


R^1 is hydrogen;

R^2 is hydrogen, alkyl, aralkyl, acyl, cycloalkyl,
hydroxy, thiol, halogen, amino, formyl, carboxy,
10 cyano, nitro, alkylthio, haloalkyl, aminoalkyl,
acylamino, alkoxy, cycloalkoxy, phenoxy, phenylalkoxy,
aminoalkoxy, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl,
alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl,
carboxyalkyl, cycloalkoxyalkyl, phenylthio,
15 alkylsulfinyl, alkylsulfonyl, phenylsulfonyl,
mercaptoalkyl, alkylthioalkyl, phenyl optionally
having substituent(s), aromatic heterocyclic group or
phenylalkyl;

R^3 is

20 (1) alkyl or haloalkyl,
(2) cycloalkyl,
(3) phenyl optionally having substituent(s),
(4) aromatic heterocyclic group,
(5) a group derived from a benzene ring fused with a
25 saturated or unsaturated 5 or 6 membered carbocyclic
ring,
(6) a group derived from a benzene ring fused with a
saturated or unsaturated 5 to 7 membered carbocyclic
ring containing 1 to 3 heteroatom(s), or
30 (7) a group derived from a 5 to 7 membered saturated
or unsaturated carbocyclic ring containing 1 to 3
heteroatom(s), which is fused with a benzene ring,
wherein the groups of (2) to (7) may have one or more

substituent(s), or
a group selected from the groups represented by the
following formulas (II) and (III):



(II)



(III)

5 wherein R^6 and R^7 are each phenyl optionally having
substituent(s) or an aromatic heterocyclic group,
or R^2 and R^3 in conjunction form a ring optionally containing
heteroatom(s), wherein the ring may be fused with a
benzene ring optionally having substituent(s);

10 R^4 is alkoxycarbonyl,
alkylcarbonyl,
alkylsulfonyl,
alkylsulfinyl,
phenylsulfinyl,
15 phenylsulfonyl,
dialkylphosphinyl,
dialkylphosphonyl,
phenyl optionally having substituent(s),
an aromatic heterocyclic group optionally having
20 substituent(s),
cyano or
nitro; and

R^5 is alkyl,
phenylaminoalkyl,
25 acyl,
acylalkyl,
aminocarbonyl,
arylaminocarbonyl,
a saturated or unsaturated 4 to 7 membered

heterocyclic ring optionally having substituent(s),
a saturated 3 to 7 membered carbocyclic ring having
substituent(s),
alkyl substituted by a saturated or unsaturated 4 to
5 7 membered ring containing 1 or 2 nitrogen atom(s),
which optionally has a substituent, or
a group of the formula: $-(CR^aR^b)_nNR^{11}R^{12}$ wherein n is
an integer of 1 to 4, R^a is hydrogen or alkyl, R^b is
hydrogen or alkyl, R^{11} is hydrogen, alkyl,
10 alkylsulfonyl, phenylsulfonyl, phenylalkylsulfonyl,
alkylsulfinyl, phenylsulfinyl, phenylalkylsulfinyl,
alkoxycarbonyl, phenoxycarbonyl, phenylalkoxycarbonyl,
alkylcarbonyl, phenylcarbonyl or phenylalkylcarbonyl,
and R^{12} is hydrogen or alkyl,
15 provided that when R^0 , R^1 and R^2 are each hydrogen, R^4 is
methoxycarbonyl and R^5 is methyl, then R^3 should not be phenyl,
2-chlorophenyl, 3-nitrophenyl, 4-carboxyphenyl or 4-
methoxycarbonylphenyl, and when R^5 is alkyl, then R^4 is not
alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, phenylsulfinyl,
20 phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, cyano or
nitro,
or an optically active form thereof, or a pharmaceutically
acceptable salt thereof.

25 13. The dihydropyrazolopyridine compound of claim 12, wherein
 R^4 is alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl,
alkylsulfinyl, phenylsulfinyl, phenylsulfonyl,
dialkylphosphinyl, dialkylphosphonyl, phenyl optionally having
substituent(s), an aromatic heterocyclic group having
30 substituent(s), cyano or nitro, and
 R^5 is alkyl, phenylaminoalkyl, acyl, acylalkyl, aminocarbonyl,
arylaminoalkyl, a saturated or unsaturated 4 to 7 membered
heterocyclic ring optionally having substituent(s), a

saturated 3 to 7 membered carbocyclic ring having
substituent(s), alkyl substituted by a saturated or
unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen
atom(s), which optionally has a substituent, or a group of the
5 formula: $-(CH_2)_nNR^{11}R^{12}$ wherein n is an integer of 1 to 4, R^{11} is
hydrogen, alkyl, alkylsulfonyl, phenylsulfonyl,
phenylalkylsulfonyl, alkylsulfinyl, phenylsulfinyl,
phenylalkylsulfinyl, alkoxycarbonyl, phenoxycarbonyl,
phenylalkoxycarbonyl, alkylcarbonyl, phenylcarbonyl or
10 phenylalkylcarbonyl, and R^{12} is hydrogen or alkyl,
or an optically active form thereof, or a pharmaceutically
acceptable salt thereof.

14. The dihydropyrazolopyridine compound of claim 12 or 13,
15 wherein R^2 is hydrogen or alkyl, or an optically active form
thereof, or a pharmaceutically acceptable salt thereof.

15. The dihydropyrazolopyridine compound of claim 12 or 13,
wherein R^3 is phenyl optionally having 1 to 3 substituent(s),
20 naphthyl, 2,1,3-benzoxadiazol-4-yl or 3,4-dihydro-2H-
benzopyran-8-yl, or an optically active form thereof, or a
pharmaceutically acceptable salt thereof.

16. The dihydropyrazolopyridine compound of claim 12 or 13,
25 wherein R^4 is alkoxycarbonyl having 2 to 5 carbon atoms,
alkylcarbonyl having 2 to 5 carbon atoms, alkylsulfonyl having
1 to 4 carbon atoms, or alkylsulfinyl having 1 to 4 carbon
atoms, or an optically active form thereof, or a
pharmaceutically acceptable salt thereof.

30

17. The dihydropyrazolopyridine compound of claim 12 or 13,
wherein R^5 is a group of the formula: $-(CH_2)_nNR^{11}R^{12}$ wherein n is
an integer of 1 to 4, R^{11} is hydrogen, alkyl or alkoxycarbonyl

and R¹² is hydrogen or alkyl, or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

18. The dihydropyrazolopyridine compound of claim 12 or 13,
5 wherein R⁰ is hydrogen or a group of the formula: -COOR⁸
(wherein R⁸ is alkyl, aryl optionally having substituent(s) or
aralkyl optionally having substituent(s)), or an optically
active form thereof, or a pharmaceutically acceptable salt
thereof.

10

19. The dihydropyrazolopyridine compound of claim 12 or 13,
which is selected from the group consisting of
(1002) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-
(piperidin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
15 (1003) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(1-
methypiperidin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
(1011) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(4-
methylmorpholin-2-yl)-2H-pyrazolo[3,4-b]pyridine,
(1014) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(1-
20 methyl-1,2,3,6-tetrahydropyridin-4-yl)-2H-pyrazolo[3,4-b]-
pyridine,
(1023) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(4-
(N,N-dimethylamino) cyclohexyl)-2H-pyrazolo[3,4-b]pyridine,
(1027) 6-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2,1,3-
25 benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-2H-pyrazolo[3,4-b]-
pyridine,
(1033) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(1-
ethylpiperidin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
(1037) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-
30 (piperidin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
(1038) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-
methypiperidin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
(1041) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-

methylpiperidin-3-yl)-2H-pyrazolo[3,4-b]pyridine,
 (1046) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(4-methylmorpholin-2-yl)-2H-pyrazolo[3,4-b]pyridine,
 (1048) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
 (1051) 6-(1-acetylpiperidin-4-yl)-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine,
 (1052) 6-(1-benzoylpiperidin-4-yl)-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine,
 (1053) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-methanesulfonylpiperidin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
 (1059) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(4-oxocyclohexan-1-yl)-2H-pyrazolo[3,4-b]pyridine,
 (1062) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(2-oxocyclohexan-1-yl)-2H-pyrazolo[3,4-b]pyridine,
 (1063) 6-acetylmethyl-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine,
 (1073) 5-cyano-4,7-dihydro-4-(2,3-(methylenedioxy)phenyl)-6-(piperidin-4-yl)-2H-pyrazolo[3,4-b]pyridine,
 (1075) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine-6-carboxylic acid phenylamide,
 (1078) 4-(2-chlorophenyl)-5-cyano-4,7-dihydro-6-(4-phenylpiperazin-1-yl)methyl-2H-pyrazolo[3,4-b]pyridine,
 (1081) 6-acetyl-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine,
 (1082) 6-acetyl-4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine,
 (1084) 4-(2-bromo-3-cyanophenyl)-5-(pyridin-2-yl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine,
 (1086) 4-(2-chlorophenyl)-5-cyano-4,7-dihydro-6-(pyrrolidin-3-yl)-2H-pyrazolo[3,4-b]pyridine, and
 (1087) 4-(2,1,3-benzoxadiazol-4-yl)-5-(pyridin-2-yl)-4,7-

5 dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine,
a tautomer thereof, an optically active form thereof, or a
pharmaceutically acceptable salt thereof.

10 20. A medicament comprising a dihydropyrazolopyridine compound
of claim 1 or 2, an optically active form thereof, a
pharmaceutically acceptable salt thereof or a hydrate thereof.

21. A medicament comprising a dihydropyrazolopyridine compound
15 of claim 12 or 13, an optically active form thereof, or a
pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising a
dihydropyrazolopyridine compound of claim 1 or 2, an optically
15 active form thereof, a pharmaceutically acceptable salt
thereof or a hydrate thereof, and a pharmaceutically
acceptable additive.

23. A pharmaceutical composition comprising a
20 dihydropyrazolopyridine compound of claim 12 or 13, an
optically active form thereof, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable
additive.

25 24. A glycogen synthase kinase-3 beta inhibitor comprising a
compound selected from the group consisting of a
dihydropyrazolopyridine compound of claim 1 or 2, an optically
active form thereof, a pharmaceutically acceptable salt
thereof and a hydrate thereof.

30 25. A glycogen synthase kinase-3 beta inhibitor comprising a
compound selected from the group consisting of a
dihydropyrazolopyridine compound of claim 12 or 13, an

optically active form thereof and a pharmaceutically acceptable salt thereof.

26. The medicament of claim 20 or 21, which is used for
5 prevention and/or treatment of a disease caused by glycogen synthase kinase-3 beta hyperactivity.

27. The medicament of claim 20 or 21, which is used for prevention and/or treatment of a neurodegenerative disease.

10

28. The medicament of claim 27, wherein the disease is selected from the group consisting of Alzheimer's disease, ischemic cerebrovascular disorders, Down's syndrome, cerebral ischemia due to cerebral amyloid angiopathy, progressive
15 supranuclear paralysis, subacute sclerosing panencephalitic Parkinsonism, postencephalitic Parkinsonism, boxer's encephalopathy, Parkinsonism dementia complex of Guam, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, AIDS encephalopathy, Huntington's
20 disease and manic-depressive psychosis.

29. The medicament of claim 20 or 21, which is used for prevention and/or treatment of diabetes and diabetic complications.

25

30. The medicament of claim 20 or 21, which is used as an immunopotentiator.

31. The medicament of claim 20 or 21, which is used for
30 prevention and/or treatment of alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia or virus-induced tumors.